HALf Of NEW CANCER DRUGS NOT SHOWING SURVIVAL GAINS
LONDON: Nearly half of new cancer drugs approved in Europe show little evidence that they are helping extend or improve life, says a new study. Even where drugs did show survival gains over existing treatments, these were often marginal, found the researchers based at King’s College London and the London School of Economics. The study published in the journal BMJ prompts calls to “raise the evidence bar” for approval of new cancer drugs. Many of the drugs were approved on the basis of indirect measures that do not always reliably predict whether a patient will live longer or feel better, raising serious questions about the current standards of drug regulation.